Lowenstein Sandler represented Inductive Bio, a technology company developing a machine learning (ML) platform designed to accelerate the compound optimization process dramatically, in a $4.3 million Seed Series funding. The seed round was co-led by Andreessen Horowitz (a16z) Bio + Health and Lux Capital, with participation from Character, Bessemer Venture Partners, Alleycorp, and others.

Inductive’s platform maps the drivers of small molecule ADMET by pairing a proprietary dataset with state-of-the-art ML, helping scientists to optimize initial compounds into leads and development candidates faster and with a better balance of ADMET properties.

The Lowenstein deal team included Eric Weiner, Laura Cicirelli, Frank W. Eucalitto, and Ike Omoruna.